BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29931766)

  • 1. Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC).
    Li RZ; Fan XX; Shi DF; Zhu GY; Wang YW; Luo LX; Pan HD; Yao XJ; Leung EL; Liu L
    Chem Biol Drug Des; 2018 Nov; 92(5):1851-1858. PubMed ID: 29931766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of the M2 Isoform of Pyruvate Kinase (PKM2) with shRNA Enhances the Effect of Docetaxel in Human NSCLC Cell Lines In Vitro.
    Yuan S; Qiao T; Zhuang X; Chen W; Xing N; Zhang Q
    Yonsei Med J; 2016 Nov; 57(6):1312-23. PubMed ID: 27593857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting pyruvate kinase M2 contributes to radiosensitivity of non-small cell lung cancer cells in vitro and in vivo.
    Meng MB; Wang HH; Guo WH; Wu ZQ; Zeng XL; Zaorsky NG; Shi HS; Qian D; Niu ZM; Jiang B; Zhao LJ; Yuan ZY; Wang P
    Cancer Lett; 2015 Jan; 356(2 Pt B):985-93. PubMed ID: 25444918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds.
    Zhang Y; Liu B; Wu X; Li R; Ning X; Liu Y; Liu Z; Ge Z; Li R; Yin Y
    Bioorg Med Chem; 2015 Aug; 23(15):4815-4823. PubMed ID: 26081759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel protein kinase C activator from Croton tiglium for inhibition of non-small cell lung cancer.
    Wang Y; Tang C; Yao S; Lai H; Li R; Xu J; Wang Q; Fan XX; Wu QB; Leung EL; Ye Y; Yao X
    Phytomedicine; 2019 Dec; 65():153100. PubMed ID: 31648127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator.
    Matsui Y; Yasumatsu I; Asahi T; Kitamura T; Kanai K; Ubukata O; Hayasaka H; Takaishi S; Hanzawa H; Katakura S
    Bioorg Med Chem; 2017 Jul; 25(13):3540-3546. PubMed ID: 28511909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism.
    Lin H; Han H; Yang M; Wen Z; Chen Q; Ma Y; Wang X; Wang C; Yin T; Wang X; Lu G; Chen H; Qi J; Yang Y
    Eur J Med Chem; 2023 Mar; 249():115166. PubMed ID: 36731272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcellular compartmentalization of PKM2 identifies anti-PKM2 therapy response in vitro and in vivo mouse model of human non-small-cell lung cancer.
    Suzuki A; Puri S; Leland P; Puri A; Moudgil T; Fox BA; Puri RK; Joshi BH
    PLoS One; 2019; 14(5):e0217131. PubMed ID: 31120964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of PKM2 Enhances Radiosensitivity of Non-small cell Lung Cancer.
    Wang S; Ma Y; Wang P; Song Z; Liu B; Sun X; Zhang H; Yu J
    Cell Biochem Biophys; 2015 Sep; 73(1):21-6. PubMed ID: 25649613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Guided Approach to Discover Tuberosin as a Potent Activator of Pyruvate Kinase M2, Targeting Cancer Therapy.
    Adnan M; Shamsi A; Elasbali AM; Siddiqui AJ; Patel M; Alshammari N; Alharethi SH; Alhassan HH; Bardakci F; Hassan MI
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors.
    Ye X; Sun Y; Xu Y; Chen Z; Lu S
    Med Chem; 2016; 12(7):613-620. PubMed ID: 26951145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor effects of novel alkannin derivatives with potent selectivity on comprehensive analysis.
    Dai ZQ; Gao F; Zhang ZJ; Lu MJ; Luo YJ; Zhang T; Shang BX; Gu YH; Zeng Q; Gao S; Guo ZQ; Xu B; Lei HM
    Phytomedicine; 2023 Aug; 117():154912. PubMed ID: 37295023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel pyruvate kinase M2 activator compound that suppresses lung cancer cell viability under hypoxia.
    Kim DJ; Park YS; Kim ND; Min SH; You YM; Jung Y; Koo H; Noh H; Kim JA; Park KC; Yeom YI
    Mol Cells; 2015 Apr; 38(4):373-9. PubMed ID: 25813626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
    Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
    Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of miR-214 inhibits proliferation and glycolysis in non-small-cell lung cancer cells via down-regulating the expression of hexokinase 2 and pyruvate kinase isozyme M2.
    Zhang K; Zhang M; Jiang H; Liu F; Liu H; Li Y
    Biomed Pharmacother; 2018 Sep; 105():545-552. PubMed ID: 29886375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model.
    Guo W; Zhang Y; Chen T; Wang Y; Xue J; Zhang Y; Xiao W; Mo X; Lu Y
    J Cancer Res Clin Oncol; 2011 Jan; 137(1):65-72. PubMed ID: 20336315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicological effects of NCKU-21, a phenanthrene derivative, on cell growth and migration of A549 and CL1-5 human lung adenocarcinoma cells.
    Liao HF; Pan CH; Chou PY; Chen YF; Wu TS; Sheu MJ; Wu CH
    PLoS One; 2017; 12(9):e0185021. PubMed ID: 28945763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis and Biological Evaluation of Quinoline-8-Sulfonamides as Inhibitors of the Tumor Cell-Specific M2 Isoform of Pyruvate Kinase: Preliminary Study.
    Marciniec K; Rzepka Z; Chrobak E; Boryczka S; Latocha M; WrzeĊ›niok D; Beberok A
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2'-hydroxycinnamaldehyde inhibits cancer cell proliferation and tumor growth by targeting the pyruvate kinase M2.
    Yoon YJ; Kim YH; Jin Y; Chi SW; Moon JH; Han DC; Kwon BM
    Cancer Lett; 2018 Oct; 434():42-55. PubMed ID: 30009856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PKM2 Knockdown Induces Autophagic Cell Death via AKT/mTOR Pathway in Human Prostate Cancer Cells.
    Dey P; Kundu A; Sachan R; Park JH; Ahn MY; Yoon K; Lee J; Kim ND; Kim IS; Lee BM; Kim HS
    Cell Physiol Biochem; 2019; 52(6):1535-1552. PubMed ID: 31135122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.